Conventional cancer therapy, such as surgery, chemotherapy, and radiation, does not have the capacity to target and kill metastatic tumor cells wherever they reside in the patient’s body. Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., a biotech company in Israel, says that attempts to develop cancer vaccines have failed because most tumors express an array of chemicals that enable it to evade the host’s immune attack, and today’s cancer vaccines haven’t been able to overcome this ability of the tumor to suppress the patient’s immune response.

However, Dr. Michael Har-Noy says that the patient’s own immune system, if properly manipulated, may indeed be capable of eliminating cancer cells wherever they reside in the body. He says that if one could harness the ability of a patient’s immune system to eliminate individual metastatic cells, the result may be a complete cure.

At Immunovative Therapies, Dr. Michael Har-Noy has developed a unique process he has termed the “Mirror EffectTM”. The Mirror EffectTM represents a breakthrough in our ability to target cancers with direct immune responses and to compromise the ability of cancer cells to avoid these responses. The development of the Mirror EffectTM and the production of compounds that utilize it may potentially create an entirely new field of medicine. Dr. Michael Har-Noy goes on to indicate that by properly patenting this proprietary technology, Immunovative Therapies can create tremendously profitable and marketable drugs.

Immunovative Therapies has been working with their patent attorneys to construct a portfolio that captures the vast depth and scope of the Mirror EffectTM and that accurately characterizes its use to manipulate the immune system to treat the most life-threatening diseases that are described in modern medicine. Dr. Michael Har-Noy indicates Immunovative Therapies’ patent portfolio will not only protect the company’s products and manufacturing techniques but may create a completely new industry based on controlling and manipulating the human immune system.

Dr. Michael Har-Noy believes that ultimately, Immunovative Therapies’ patent portfolio will probably introduce a new completely new branch of oncologic practice and completely revolutionize the way cancer is treated. This new technology will be of virtually limitless value.